The Impact of Hepatitis C Virus Entry on Viral Tropism  by Ding, Qiang et al.
Cell Host & Microbe
MinireviewThe Impact of Hepatitis C
Virus Entry on Viral TropismQiang Ding,1 Markus von Schaewen,1 and Alexander Ploss1,*
1Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA
*Correspondence: aploss@princeton.edu
http://dx.doi.org/10.1016/j.chom.2014.10.009
Uptake of hepatitis C virus (HCV) into hepatocytes is an orchestrated process, involving numerous host
factors, virion-associated lipoproteins, and a growing number of cell-associated factors. Several of these
factors likely contribute to the hepatotropism and limited host range of this virus. Discerning the minimal
set of human-specific factors required for viral uptake into nonhuman cells has facilitated the development
of small animal models with inheritable HCV susceptibility. This review summarizes current knowledge of
host factors required for HCV entry, the molecular mechanisms underlying HCV entry into hepatocytes,
and aspects of viral entry contributing to HCV host tropism.INTRODUCTION
At least 150 million people worldwide are currently infected with
hepatitis C virus (HCV), although this value is most likely an un-
derestimation, as almost twice asmany individuals as diagnosed
may carry the virus. HCV causes persistent infection in 70%–
80% of those who are exposed. While the acute disease is usu-
ally asymptomatic, chronic carriers frequently develop fibrosis,
cirrhosis, and, in some cases, hepatocellular carcinoma, espe-
cially if left untreated. The treatment for HCV has evolved rapidly
in recent years. Previous therapies based on a combination of
pegylated interferon (IFN) alpha and ribavirin were only partially
effective and poorly tolerated by patients. However, new
direct-acting antivirals (DAAs) and, most recently, all-oral IFN-
free regimens have been proven highly effective across all HCV
genotypes and in almost all patient populations. Yet the high
costs, logistical challenges of mass deployment, and the risk
of drug resistance associated with even the newest DAAs are
considerable obstacles that must be overcome if global levels
of HCV are to be reduced. A vaccine, which would prevent
infection or delay the onset of pathogenesis during a chronic
infection, still does not exist. Additionally, development of other
effective therapies has been delayed by the lack of suitable cell
culture systems and animal models. While hepaciviruses similar
to HCV have been found in a variety of species, including dogs,
horses, and outbred mice, HCV has a much more limited host
range. While some studies have provided evidence for transient
and intermittent viremia in more exotic species such as tree
shrews, robust infection has only been described in humans
and experimentally infected chimpanzees. Although this narrow
host range of HCV is not fully understood, it can partially be ex-
plained, as described in this review, by differences in the se-
quences of host factors essential for viral entry.
HCV is an enveloped, positive-strand RNA virus of the genus
hepacivirus in the Flaviviridae family. The 9.6-kb RNA genome
is flanked by 50 and 30 nontranslated regions and contains two
open reading frames, with one encoding the entire HCV polypro-
tein and the other producing a single gene product, the so-called
‘‘mini core’’ (reviewed in Moradpour et al., 2007). The HCV poly-
protein is processed by host- and virus-encoded proteases,562 Cell Host & Microbe 16, November 12, 2014 ª2014 Elsevier Inc.releasing ten mature proteins: the structural proteins, which
include the core protein and the envelope glycoproteins E1
and E2; the viroporin p7; and the nonstructural (NS) proteins
NS2, NS3, NS4A, NS4B, NS5A, and NS5B. The viral envelope
proteins E1 and E2 are critically important for viral uptake into he-
patocytes.
HCV entry is a highly coordinated process, requiring in addi-
tion to E1 and E2 a plethora of host cell factors, some of which
contribute to the hepato- and human tropism of HCV. Here, we
aim to provide a concise overview of the mechanism of HCV en-
try, its impact on hepato- and human tropism of HCV, and its
subsequent implications for HCV animal model development.
HCV Particle
The known viral components of the HCV virion are genomic RNA,
the core protein, and the envelope glycoproteins E1 and E2.
These glycoproteins are believed to form a noncovalent hetero-
dimer, stabilized by disulfide bridges, and help mediate receptor
binding and entry into hepatocytes. As detailed below, HCV is
internalized through receptor-mediated endocytosis. The viral
membrane must first fuse with the endosomal membrane, thus
allowing the RNA genome to gain access to the cytoplasmwhere
it is translated (see review by Paul et al., 2014 in this issue). This
process is triggered through acidification of the endosomal
compartment, which is thought to result in a conformational
change of the viral envelope (Figure 1). Based primarily on
computational analysis, E2 was predicted to be a class II fusion
protein with a highly extended conformation of three predomi-
nantly b sheet domains (Krey et al., 2010). However, recent
crystal structures of the core HCV E2 domain demonstrate that
it has a compact globular structure distinctly different from the
extended, multidomain envelope-protein structures of related
pestiviruses and flaviviruses (Khan et al., 2014; Kong et al.,
2013). This suggests that HCV may follow a different fusion
process involving E1, which has been predicted to contain a
putative fusion peptide (Flint et al., 1999; Takikawa et al.,
2000). In addition, recent studies suggest E1 may have a critical
role inmodulating HCV binding to receptors (Douam et al., 2014).
Based on EM studies, it is thought that HCV particles have a
diameter of 40–75 nm. In contrast to related enveloped RNA
Figure 1. Putative Mechanism of HCV Entry
(A) Lipoviral HCV particles attach to HSPG, LDLR,
and SCARB1.
(B) Interaction with SCARB1 induces conforma-
tional changes in HCV E2, leading to binding of E2
to CD81.
(C) CD81 binding activates signaling pathways via
EGFR, Ras, and Rho GTPases, triggering lateral
membrane diffusion of HCV. The exact roles
of TfR1, NPC1L1, CLDN1, and OCLN are not
defined, but they are engaged in steps post viral
attachment and HCV binding to CD81.
(D) Interaction of the HCV E2-CD81/CLDN1-
complex initiates clathrin-mediated endocytosis.
(E) Promoted by an interaction with CIDEB, the
viral envelope and the endosomal membrane un-
dergo fusion in a low-pH environment.
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obvious symmetry or surface features (reviewed in Lindenbach
and Rice, 2013). The morphology and low buoyant density of
HCV particles is due to their interaction with host lipoproteins.
Biochemical analyses of HCV particles derived from patient
sera revealed an association with the lipoprotein components
apolipoprotein A-I (apoA-I), apoB-48, apoB-100, apoC-I, and
apoE (reviewed in Bartenschlager et al., 2011). Similarly, cell-cul-
ture-derived HCV particles interact with apoE and apoC-I and
have a high lipid and cholesterol content. These observations
have given rise to the concept of an HCV lipoviroparticle (LVP),
which can engage high- and low-density lipoprotein receptors
during viral uptake into hepatocytes. In addition, association
with lipoproteins may also help the virus escape neutralizing
antibodies.
HCV Entry Factors
Numerous host factors have been implicated in the uptake of
HCV into human hepatocytes, including glycosaminoglycans
(GAGs) present on heparan sulfate proteoglycans (HSPGs),
low-density lipoprotein receptor (LDLR) (Agnello et al., 1999),
CD81 (Pileri et al., 1998), scavenger receptor class B member 1
(SCARB1) (Scarselli et al., 2002), the tight junction proteins clau-
din-1 (CLDN1) (Evans et al., 2007) and occludin (OCLN) (Liu et al.,
2009; Ploss et al., 2009), the receptor tyrosine kinases epidermal
growth factor receptor (EGFR) and ephrin receptor A2 (EphA2)
(Lupberger et al., 2011), the cholesterol transporter Niemann-Cell Host & Microbe 16, NPick C1-like 1 (NPC1L1) (Sainz et al.,
2012), transferrin receptor 1 (TfR1)
(Martin and Uprichard, 2013) and the
cell-death-inducing DFFA-like effector b
(CIDEB) (Wu et al., 2014) (Figure 1).
In addition, the C-type lectins liver-/
lymph-node-specific intercellular adhe-
sion molecule-3-grabbing integrin (L-
SIGN) (Cormier et al., 2004), expressed
on liver sinusoidal endothelial cells, and
the dendritic-cell-specific intercellular
adhesion molecule-3-grabbing noninte-
grin (DC-SIGN), present on dendritic cells
and liver resident macrophages, can bind
to HCV E2 (Gardner et al., 2003; Lozachet al., 2003; Po¨hlmann et al., 2003). Conceivably, C-type lectins
on sinusoidal cells may be able to capture HCV in the liver, but it
is unclear whether this can lead to productive infection of hepa-
tocytes in trans or whether sequestered HCV is subjected to
lysosomal degradation.
CD81 was the first molecule to be identified as an HCV recep-
tor, directly binding the soluble form of HCV E2 (Pileri et al.,
1998). CD81 is a ubiquitously expressed tetraspanin, containing
a small extracellular and a large extracellular loop (LEL). The LEL
seems to play an important role in mediating the interaction of
CD81 with E2, as soluble recombinant human CD81 LEL can
inhibit infections with cell-culture-derived HCV (HCVcc) and len-
tiviral pseudoparticles bearing HCV glycoproteins (HCVpp)
(Zhang et al., 2004). Time course studies with CD81-specific an-
tibodies, which block HCV infection, suggest that CD81 medi-
ates a postbinding event in HCV entry (Bertaux and Dragic,
2006). Consistent with this, the CD81-binding region of E2 is ob-
structed by its hypervariable region 1 (HVR1), suggesting that
native E2 undergoes a conformational change before its engage-
ment with CD81 (Bankwitz et al., 2010).
SCARB1 was identified as an HCV receptor by its ability to
bind recombinant HCV E2 (Scarselli et al., 2002). SCARB1 is
highly expressed in the liver and can bind high-density lipopro-
teins (HDLs), very-low-density lipoproteins (VLDLs), and
oxidized forms of LDLs, mediating the uptake of cholesterol
from these lipoproteins by hepatocytes. SCARB1 is a glycopro-
tein with cytoplasmic N- and C-terminal domains separated by aovember 12, 2014 ª2014 Elsevier Inc. 563
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has multiple stepwise roles during HCV entry. First, the initial
attachment of HCV particles to SCARB1 is mediated by virus-
associated lipoproteins, such as apoE, which is present on
HCV LVPs. Second, the lipid transfer function of SCARB1 may
facilitate the exposure of CD81 binding sites on HCV E2 and
transfer of the virus particle to CD81. Finally, direct interactions
between SCARB1 and the HVR1 of E2 enhance infectivity of
the particle after attachment (Bartosch et al., 2005). Together,
these studies suggest that HCV entry results from a complex
interplay between lipoproteins, SCARB1, and HCV envelope
glycoproteins.
CLDN1 is a member of the claudin family of tight junction pro-
teins and is expressed in many epithelial tissues, including the
liver. CLDN1 was identified as an essential HCV entry factor
through expression cloning of a cDNA that made HEK293 cells
permissive to HCVpp entry (Evans et al., 2007). Recent studies
suggest that HCV E1 but not E2 may directly interact with
CLDN1 (Douam et al., 2014). During the HCV entry process,
CLDN1 interacts with CD81, forming a complex critical for virus
internalization. Other members of the claudin family, specifically
CLDN6 and CLDN9, can also mediate HCV entry (Zheng et al.,
2007). However, usage of different claudins appears to be
dependent on the HCV isolate (Haid et al., 2014), but less in hu-
man hepatocytes (Fofana et al., 2013).
Using a similar cDNA expression cloning strategy, another
tight junction protein, OCLN, was identified as a missing host
factor needed to facilitate HCV uptake into mouse and hamster
cell lines expressing human CD81, CLDN1, and OCLN (Ploss
et al., 2009). Gain- and loss-of-function studies also established
the critical role of OCLN for HCV entry into human cells. OCLN is
a four-transmembrane protein expressed in the tight junctions of
polarized cells. To date, there is no experimental evidence
demonstrating a direct interaction of OCLN with the HCV glyco-
proteins. Although the exact role of OCLN in viral uptake is not
completely understood, it appears to function at a postattach-
ment step in HCV entry (Sourisseau et al., 2013b).
NPC1L1 is a 13-transmembrane-domain cholesterol-sensing
cell surface receptor expressed on the apical surface of intestinal
enterocytes and human hepatocytes. NPC1L1 is responsible
for cellular cholesterol absorption and whole-body cholesterol
homeostasis. Ezetimibe is a 2-azetidinone–class drug that
has been shown to be a direct inhibitor of NPC1L1 internaliza-
tion. An ezetimibe-mediated inhibition assay suggested that
NPC1L1 reduces HCV entry at a postbinding, prefusion step
(Sainz et al., 2012). Given their high expression in hepatocytes,
NPC1L1, CLDN1, and SCARB1 may largely define the hepato-
tropism of HCV at the level of entry.
TfR1 is ubiquitously expressed in all tissues and is the main
receptor for cellular iron uptake via clathrin-mediated endocy-
tosis. Interestingly, HCV infection can decrease TfR1 expression,
and TfR1 has been found to bind HCV viral particles. Time-of-
addition experiments using anti-TfR1 antibodies indicate that
TfR1 may play a role in HCV uptake after the virus engages
CD81 (Martin and Uprichard, 2013). However, further studies
are needed to clarify the exact roles of TfR1 contributing to
HCV entry.
Receptor tyrosine kinases EGFR and EphA2 were identified
as HCV entry factors using a functional RNAi kinase screen.564 Cell Host & Microbe 16, November 12, 2014 ª2014 Elsevier Inc.The compounds erlotinib (a specific inhibitor of EGFR) and da-
satinib (a specific inhibitor of EphA2) can block HCV entry into
hepatocytes (Lupberger et al., 2011). It should be noted that
EGFR does not directly interact with the HCV particle, but
EGFR-dependent signaling promotes the formation of CD81-
CLDN1 complexes, which is required for HCV entry (Lindenbach
and Rice, 2013).
Recently, CIDEB has been implicated in HCV uptake (Wu et al.,
2014). CIDEB is highly expressed in the liver and is one of the
members of the cell-death-inducing DFFA-like effector (CIDE)
protein family. Based on an infection time course assay and
the fact that CIDEB affects uptake of HCVcc but not HCVpp, it
appears that CIDEB functions in a late step of HCV entry,
possibly to facilitate membrane fusion. However, the precise
mechanism by which HCV utilizes CIDEB for entry is not known.
Putative Mechanism of HCV Entry
HCV entry is a highly orchestrated process requiring tight spatial
control and temporal engagement of cellular cofactors (Figure 1).
GAGs, LDLR, and SCARB1 are thought to mediate the initial
attachment of the lipoprotein-associated HCV particles to the
surface of hepatocytes. The interaction with SCARB1 is believed
to aid in the dissociation of HCV-associated lipoproteins from
viral particles and induce conformational changes in the HCV
E2 glycoprotein, exposing the CD81 interaction domains. It is re-
ported that TfR1 is engaged at a post-CD81 step in HCV entry,
but the precise role is not known (Martin and Uprichard, 2013).
Likewise, OCLN functions at a postbinding stage prior to endo-
somal acidification (Sourisseau et al., 2013b). Engagement of
E2 with CD81 subsequently activates signaling pathways via
EGFR andH-Ras, aswell as through RhoGTPases, which trigger
lateral membrane diffusion of HCV-CD81 complexes to the tight
junction (Lupberger et al., 2011; Zona et al., 2013). The interac-
tion of HCV-CD81 complexed with CLDN1 is thought to induce
clathrin-mediated endocytosis. Following uptake, HCV corecep-
tor complexes are trafficked to early endosomes for HCV fusion.
The interaction of E2 with CD81 induces fusion between the viral
envelope and the endosomal membrane in a low-pH environ-
ment. Following fusion, HCV genomic RNA is released from
the viral nucleocapsid into the cytosol, where it is translated
into viral proteins, initiating the subsequent steps in the HCV
life cycle.
The entry mechanisms described above are thought to mostly
apply to cell-free HCV particle transmission. In addition, HCV
can spread to neighboring hepatocytes via direct cell-to-cell
transmission. In contrast to cell-free HCV particle transmission,
HCV may be shielded from neutralizing antibodies during cell-
to-cell transmission, aiding the establishment of persistent infec-
tion. Recent studies have also demonstrated that cell-to-cell
transmission may be a major transmission route for antiviral-
resistant strains, thus highlighting the importance of studying
this process further. HCV cell-to-cell transmission is dependent
on numerous host factors also required during cell-free entry,
including SCARBI, CLDN1, OCLN, EGFR, EphA2, and NPC1L1
and possibly CD81. In contrast, the VLDL pathway, which is
required for the secretion of cell-free infectious virus, does not
seem to be required for cell-to-cell transmission. In addition,
TfR1 is involved in HCV cell-free entry but has a less prominent
role in cell-to-cell transmission (Barretto et al., 2014).
Table 1. Expression of HCV Entry Factors in Humans and Mice
Gene in
Human
Gene in
Mouse Tissue Expression in Human Tissue Expression in Mouse
Liver Expression
in Human
Liver Expression
in Mouse
Protein
Identity (%)
LDLR Ldlr Ubiquitous Ubiquitous + + 79
SCARB1 Scarb1 Adrenal tissue, placenta, liver Adrenal gland, ovary, liver + + 80
CD81 Cd81 Ubiquitous Ubiquitous + + 92
CLDN1 Cldn1 Ubiquitous Most abundantly skin, liver + + 91
CLDN6 Cldn6 Ubiquitous Placenta + Low 87
CLDN9 Cldn9 Heart, muscle Pituitary, pancreas + Low 97
OCLN Ocln Tight junctions Tight junctions + + 89
EGFR Egfr Placenta, prostate, liver Liver, cornea, osteoblast + + 88
EphA2 Epha2 Epithelial, endothelial cells Epithelial, endothelial cells + + 92
TfR1 Tfr1 Early erythroid cells, liver Bone marrow, placenta, liver Low Low 77
NPC1L1 Npc1l1 Ubiquitous Small intestine +  77
CIDEB Cideb Liver, small intestine Liver, small intestine, kidney + + 86
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While HCV can establish chronic infections in humans, chim-
panzees, and, to a limited extent, tree shrews, other species,
including rodents and smaller, nonhuman primates, appear to
be resistant to infection. Although the basis of this highly
restricted species tropism is not completely understood, several
studies have demonstrated that it is partially defined at the level
of viral entry. Previous reports showed that CD81 from various
nonhuman primate species could facilitate HCVpp uptake into
human HepG2 hepatoma cells, which lack endogenous expres-
sion of CD81 (Flint et al., 2006). However, mice remained insus-
ceptible to HCV infection, even upon transgenic expression of
human CD81 (Masciopinto et al., 2002), indicating that other hu-
man-specific factors might be required to facilitate HCV entry
into murine cells. Subsequent work revealed that human
OCLN rendered mouse cells permissive for HCV and therefore
was the missing factor needed to overcome the HCV species
barrier at the level of entry (Ploss et al., 2009). While CD81,
SCARB1, CLDN1, and OCLN were ultimately shown to all be
required for uptake into mouse cells, CD81 and OCLN consti-
tute the minimal set of human-specific factors needed for viral
uptake into mouse or hamster cells (Ploss et al., 2009). As
was the case for CD81, primate orthologs of OCLN functioned
like the human counterpart, whereas canine, hamster, mouse,
and rat OCLN had intermediate to low activities, and guinea
pig OCLN was completely nonfunctional (Michta et al., 2010).
These observations can partially be explained by differences
between the second extracellular loops of both CD81 and
OCLN from humans and nonpermissive species (Flint et al.,
2006; Michta et al., 2010). In contrast, the residues within the
first extracellular loop of CLDN1 needed for HCV uptake (Evans
et al., 2007) are conserved between mice and humans, explain-
ing the observation that mouse CLDN1 can support viral entry.
Although it was originally demonstrated that human but not
mouse SCARB1 could bind soluble HCV E2 (Scarselli et al.,
2002) both in vitro (Ploss et al., 2009) and in vivo (Dorner
et al., 2011, 2013), infection assays demonstrated that mouse
and human SCARB1 were equally functional. These findings
suggest that HCV E2 binding may not be a reliable proxy for
functional entry assays.CeTo date, the varying susceptibility of nonhuman cells to HCV
entry is largely accounted for by differences at critical residues
within orthologs of CD81, SCARB1, CLDN1, and OCLN or by
insufficient expression of these proteins. However, the contribu-
tion of other human entry factors to the species tropism of HCV
has yet to be determined. The human and murine orthologs of
the entry factors described in this paper share a high degree of
sequence similarity (Table 1). However, differences in individual
residues can drastically affect viral uptake efficiency. NPC1L1
and TfR1, which are both highly expressed in human hepato-
cytes, were shown to be important for HCV uptake in human
cells. In contrast, mouse fibroblasts expressing human CD81
and OCLN, but not NPC1L1 and TfR1, can still support HCV en-
try (Vogt et al., 2013). Furthermore, while the murine ortholog of
NPC1L1 is abundantly expressed only in the gut and not in the
liver, HCV is still capable of entering into hepatocytes of mice
modified to express a combination of human CD81 and OCLN
(Dorner et al., 2013; Dorner et al., 2011). This suggests some
level of redundancy for NPC1L1 in HCV uptake in mouse cells.
It is conceivable but remains to be experimentally tested if
HCV entry into mouse hepatocytes would possibly become
more efficient if human TfR1 and NPC1L1 were ectopically coex-
pressed in the mouse liver along with human CD81 and OCLN.
The observation that CD81 and OCLN comprise the minimal
set of human factors required to facilitate HCV uptake into rodent
cell lines hinted how a mouse supporting HCV entry would need
to be engineered. Indeed, it was shown that adenoviral delivery
or transgenic expression of human CD81 and OCLN is sufficient
to allow HCV infection of fully immunocompetent inbred mice
(Dorner et al., 2011, 2013). Using intergenotypic virus chimeras
expressingCre recombinase to activate a cellular reporter in vivo,
HCV glycoprotein-mediated uptake of diverse HCV genotypes
can be conveniently quantified by bioluminescent imaging
(Figure 2). This platform has been used to genetically dissect
HCV entry in vivo and to evaluate preclinically passive and active
immunization strategies (Dorner et al., 2011). When crossed to
immunodeficient backgrounds, HCV entry factor transgenic
mice support the entire HCV life cycle (Dorner et al., 2013), sug-
gesting that immune-mediated restrictions exist postentry and
are not entirely insurmountable.ll Host & Microbe 16, November 12, 2014 ª2014 Elsevier Inc. 565
Figure 2. Approaches to Overcome
Species-Specific Blocks of HCV Entry and
In Vivo Visualization of HCV Entry
(A) The second extracellular loops of OCLN (blue)
and CD81 (red) are responsible for the species
tropism of viral entry.
(B) Genetic viral and host adaptation approaches.
Mouse CD81-adapted HCV can enter mouse cell
lines expressing mouse orthologs of CD81 and
OCLN.
(C) Transgenic or adenoviral expression of human
HCV entry factors facilitates HCV entry into mouse
cells in vitro and in vivo. HCV uptake can be
visualized in vivo using a cellularly encoded re-
porter that is activated by HCV expressing Cre-
recombinase (HCV-Cre).
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facilitate viral uptake into hepatocytes of nonpermissive species,
it was shown that the HCV envelope proteins can be adapted to
use entry factor orthologs from other species. Taking advantage
of the high mutational plasticity of HCV, the viral envelope pro-
teins were adapted to utilize mouse CD81more efficiently (Bitze-
geio et al., 2010). Three adaptive mutations in HCV E1 and E2
were shown to be responsible for the observed gain-of-function
phenotype. Interestingly, the resulting mouse CD81-adapted
HCVwas also capable of engagingmouseOCLNmore efficiently
and had a lower dependency on SCARB1. Although it remains
to be demonstrated whether mouse CD81-adapted HCV is
capable of infecting mouse hepatocytes in vivo, this study pro-
vides an important proof-of-concept for the feasibility of adapt-
ing HCV to engage orthologs of essential host factors from
other species. Interestingly, recent studies suggest that these
mutations also facilitate more efficient HCV uptake in stem-566 Cell Host & Microbe 16, November 12, 2014 ª2014 Elsevier Inc.cell-derived hepatocyte-like cells from
pigtailed macaques (Sourisseau et al.,
2013a). A suitable explanation for the
broadened host range of this particular
virus could be conformational changes
in the virion envelope as a result of the
three described mutations in E1 and E2.
However, some caution is warranted, as
it remains to be tested whether mouse
CD81-adapted HCV faithfully recapitu-
lates viral entry.
Perspectives
HCV entry is a highly orchestrated pro-
cess influenced not only by cell- but
also virion-associated host factors.
Many of the essential host factors
required for viral uptake into human cells
have been identified, yielding potential
targets for therapeutic interventions and
providing insights into the determinants
governing HCV tissue and host tropism.
Defining the minimal set of human-spe-
cific factors required for rendering rodent
cells permissive to HCV uptake has
facilitated the construction of mice withinheritable susceptibility to HCV infection. These genetically
humanized animals show promise as a tractable small animal
model for HCV, but additional refinements are still needed to
increase the robustness of the system.
A major challenge remains to define the exact roles of the
numerous entry factors in this complex and finely controlled pro-
cess of viral entry. HCV pseudoparticles have undoubtedly
played a critical role in the discovery of some of the entry factors
and are also particularly useful for analyzing HCV entry into cells
that do not readily support HCV RNA replication. However, given
the distinct biophysical properties of HCV particles, it remains
important to use LVPs produced in cells with an intact VLDL
pathway. Many host factors involved in viral uptake have been
identified both in hepatoma cells and in nonhepatic cells. How-
ever, neither faithfully recapitulates the polarized cellular archi-
tecture of hepatocytes in the liver. Primary cell culture systems
using human adult primary hepatocytes, fetal hepatoblasts, or
Cell Host & Microbe
Minirevieweven stem-cell-derived hepatocyte-like cells have been devel-
oped as a more physiologically relevant platform to study viral
uptake. Integrating available in vivo platforms amenable to
genetic manipulations will ultimately allow us to dissect HCV
uptake and other parts of the viral life cycle in the 3D context
of the liver.
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